Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? - Wikidata - wikimedia - TriplyDB

Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?

Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?

http://www.wikidata.org/entity/Q37414453

about

Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculation Regional therapies for in-transit disease Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion.Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.Predicting disease progression after regional therapy for in-transit melanoma.A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion.Optimizing regional infusion treatment strategies for melanoma of the extremities Pharmacotherapy of regional melanoma therapy.Regional treatment strategies for in-transit melanoma metastasis.Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review.Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion.Treatment of locally advanced melanoma by isolated limb infusion with cytotoxic drugs Australian Multicenter Study of Isolated Limb Infusion for Melanoma.Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma.Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma.Is melphalan dose adjustment according to ideal body weight useful in isolated limb infusion for melanoma?

P2860

Q21245599-AA0D29A5-14E2-4EF3-BFCD-431E07444C46 Q28087553-4CD06DB4-CB57-433E-BBFF-4FF7B90B21E0 Q34464096-34875AAE-6660-46FC-91E6-71C636CE1E4A Q35127039-1F4F4BCA-4145-4031-B088-8B560B852375 Q35471445-945B44B9-8CE7-414D-A9F4-0FC8CA1481AB Q35731493-64AF5325-0A0B-4C4B-ACC4-05BB27B3DFD7 Q36343055-9B3939E2-C7F8-4B73-8491-6C85126C9FD5 Q37509683-DB217F03-E57E-4DE1-9EE5-BB51C0AF36AC Q37509704-9381DB9C-F5F2-4584-87FF-A6CB8234CB1B Q37628698-DC09CE73-B29E-442B-8E52-B6EC1D1F4D40 Q37650312-2B522F59-5F49-433A-B907-E0BC1A610D79 Q37812815-0C3B82F1-11CD-4314-8578-5952B6F28FE1 Q37943015-75B36A07-86BC-4177-99EB-96F36F46799A Q38187594-C5EAA5AC-6DA5-4A3F-8484-D1C16715C622 Q38245172-4A39A064-1622-4142-92A6-65AA9CB377A0 Q39720293-B2369541-9041-4885-A98C-4194158F9687 Q40307423-D7D298FE-867D-4463-BA89-3B4FD2B176FC Q40317761-EEA79210-C75E-4CB2-846D-FF7C9EB95AFE Q44752180-BA150790-03F8-45F2-B333-4A0B9386A9B9 Q47314106-7DCCB7A6-92F4-422A-89C3-E920BF692C98

P2860

Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?

http://www.wikidata.org/entity/Q37414453

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 30 January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Optimizing melphalan pharmacok ...... regional response or toxicity?

@en

Optimizing melphalan pharmacok ...... regional response or toxicity?

@nl

type

label

Optimizing melphalan pharmacok ...... regional response or toxicity?

@en

Optimizing melphalan pharmacok ...... regional response or toxicity?

@nl

prefLabel

Optimizing melphalan pharmacok ...... regional response or toxicity?

@en

Optimizing melphalan pharmacok ...... regional response or toxicity?

@nl

P1433

Q37414453-906C8FE9-2AF0-4C2B-811F-85B094370EC7

P1476

Q37414453-26E419DF-6530-437E-A763-92A3FA1DADDD

P2093

Q37414453-1536DAAF-6D7C-4D25-8891-ABD08D4D45D6

Q37414453-15D8F93D-DA64-4510-A8A1-FB9812A787AC

Q37414453-31268877-B2D4-4C61-8517-B99E92221A62

Q37414453-3FBF253A-88C4-4CFD-8672-20AA4D18F9CC

Q37414453-4438C25D-721C-4867-AA1E-07E2412DBFF1

Q37414453-7EC55040-6E5A-4B7B-B09E-884F3D75D872

Q37414453-88C4197B-48DE-4224-8227-FC8600929794

Q37414453-9946BB86-7FA3-4AE5-9DE1-DAF5DCB49AFD

Q37414453-A9D42893-5F9D-4CD7-9D9C-A37B5FEA6A74

P2860

Q37414453-19F8B9C7-BB50-4A80-8272-3FEB475BFAE4

Q37414453-42639BC4-01E4-47D3-9F96-86188AE3CD07

Q37414453-47F04167-DDB0-4A1B-8D9F-EB5874279300

Q37414453-4E125DB4-735D-46DA-A993-44BE57B630C6

Q37414453-536BF316-BBFB-4214-BC30-442C2566FAD8

Q37414453-667DDD2C-BCEF-416E-B5E2-0CA59B842AF1

Q37414453-6830D4D0-2B2D-4CAC-80CA-6B7DDED389DE

Q37414453-68D2C6B5-B53B-4E65-9F20-E1E231163840

Q37414453-86D52899-D847-4B71-8843-E63709C9D9C3

Q37414453-F04EAA9D-68EB-4BA7-9509-774DC0820D9C

P2888

Q37414453-7B4CB639-D89D-4B3F-90C0-BA39518B7EE2

P304

Q37414453-7A70E3E6-E1E4-4932-B6FF-AC2904E695BD

P31

Q37414453-EED1789C-DF0F-42EA-B729-162C9B656655

P356

Q37414453-17B015C1-6B01-46C3-9B4A-283156C0DFDF

P433

Q37414453-319214D7-49FB-4898-A1F6-E7C28EBD8A3C

P478

Q37414453-D514582C-9FC0-4B12-A27D-B6BDBE2931FD

P50

Q37414453-B0E1EC6F-BF2C-44AF-B491-9E025872E1DC

P577

Q37414453-CC2296C2-88E2-41AB-94FD-92AB64DD2278

P6179

Q37414453-1F530C97-CA7D-4592-9011-F39231E6AD39

P698

Q37414453-DD174B3D-7DC1-41D0-B3E9-69B75630F7BE

P932

Q37414453-FA132C78-BFF7-4812-BA79-3FB90D7C505F

P356

S10434-008-0288-1

P1433

Annals of Surgical Oncology

P1476

Optimizing melphalan pharmacok ...... regional response or toxicity?

@en

P2093

C K Augustine

http://www.w3.org/2001/XMLSchema#string

Douglas S Tyler

http://www.w3.org/2001/XMLSchema#string

G Sanders

http://www.w3.org/2001/XMLSchema#string

I Spasojevic

http://www.w3.org/2001/XMLSchema#string

J C Padussis

http://www.w3.org/2001/XMLSchema#string

N McMahon

http://www.w3.org/2001/XMLSchema#string

P Zipfel

http://www.w3.org/2001/XMLSchema#string

T Y Cheng

http://www.w3.org/2001/XMLSchema#string

W Petros

http://www.w3.org/2001/XMLSchema#string

P2860

Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion.

The cellular and molecular basis of hyperthermia.

The role of hyperthermia in regional alkylating agent chemotherapy.

A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.

Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.

Outcomes following isolated limb infusion for melanoma. A 14-year experience.

A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.

Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.

A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma.

Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity.

P2888

s10434-008-0288-1

P304

953-961

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-008-0288-1

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Georgia Beasley

P577

2009-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1039685498

http://www.w3.org/2001/XMLSchema#string

P698

19184236

http://www.w3.org/2001/XMLSchema#string

P932

3872993

http://www.w3.org/2001/XMLSchema#string